Results 61 to 70 of about 1,740,352 (427)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer

Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 81-90, January 2023., 2023
XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.
Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto, Yoshinori Kagawa, Mitsuyoshi Tei, Yoshihito Ide, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi, Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO)   +16 more
wiley   +1 more source

Cell Culture Systems for Studying Hepatitis B and Hepatitis D Virus Infections

Life, 2023
The hepatitis B virus (HBV) and hepatitis D virus (HDV) infections cause liver disease, including hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). HBV infection remains a major global health problem.
Grace Sanghee Lee, Michael A. Purdy, Youkyung Choi   +2 more
doaj   +1 more source

METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response

FEBS Open Bio, EarlyView.
Liver‐specific knockout of N6‐methyladenosine (m6A) methyltransferase METTL3 significantly accelerated hepatic tumor initiation under various oncogenic challenges, contrary to the previously reported oncogenic role of METTL3 in liver cancer cell lines or xenograft models. Mechanistically, METTL3 deficiency reduced m6A deposition on Manf transcripts and
Bo Cui, Silin Tu, Haibo Li, Zhancheng Zeng, Ruiqi Xiao, Jing Guo, Xiaoqi Liang, Chang Liu, Lijie Pan, Wenjie Chen, Mian Ge, Xiaofen Zhong, Linsen Ye, Huaxin Chen, Qi Zhang, Yan Xu   +15 more
wiley   +1 more source

Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study

Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 138-146, January 2023., 2023
High tumor budding is a new candidate for an additional determinant of the T category in staging ICC. An LCSGJ staging system containing an additional evaluation of tumor budding may lead to improved staging accuracy. Abstract Purpose This retrospective study evaluated our hypothesis that high tumor budding (≥10 buds) may help determine the appropriate
Hisashi Kosaka, Mitsuaki Ishida, Masaki Ueno, Koji Komeda, Daisuke Hokutou, Hiroya Iida, Fumitoshi Hirokawa, Kosuke Matsui, Mitsugu Sekimoto, Masaki Kaibori   +9 more
wiley   +1 more source

Autoimmune hepatitis and overlap syndrome among Alaska Native people: Prevalence, clinical characteristics, and remission

JGH Open, 2023
Background and Aim High autoimmune hepatitis (AIH) and overlap syndrome (OS) prevalence have been previously documented among Alaska Native people. The purpose of this project is to report changes in AIH/OS prevalence over time, clinical characteristics,
Janet M. Johnston, Brian McMahon, Lisa Townshend‐Bulson, Julia Plotnik, Paarth Jain, Meggan Judge, Wileina Rhodes, Chriss Homan   +7 more
doaj   +1 more source

Correlation between hepatitis B G1896A precore mutations and HBeAg in chronic HBV patients [PDF]

, 2015
Background: Hepatitis B virus (HBV) infection is an important health concern worldwide, with critical outcomes. Hepatitis B e antigen (HBeAg) negative chronic hepatitis B is frequently caused by a mutation (G1896A) in the hepatitis B virus (HBV) precore (
Adli, A.H., Karami, C., Khodabakhshi, B., Moradi, A., Tabarraei, A., Zhand, S.   +5 more
core   +1 more source

Reconstitution of CXCR3+ CCR6+ Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang, Tian‐Xiang Zhang, Jia Liu, Zhirui Liu, Lijie Zhu, Yan‐Yan Li, Bin Feng, Moli Fan, Fu‐Dong Shi, Chao Zhang   +9 more
wiley   +1 more source

Current status of liver transplantation for non‐B non‐C liver cirrhosis and hepatocellular carcinoma

Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 42-52, January 2023., 2023
Recently, the cases of LT for non‐B non‐C cirrhosis and HCC have been increasing in Japan as well as worldwide. Perioperative management of non‐B non‐C liver disease is problematic due to various risk factors, including alcohol consumption and metabolic syndrome‐related risks, such as obesity and diabetes mellitus.
Takahiro Nishio, Takashi Ito, Koichiro Hata, Kojiro Taura, Etsuro Hatano   +4 more
wiley   +1 more source

Non-invasive Assessment of Hepatic Venous Pressure Gradient (HVPG) Based on MR Flow Imaging and Computational Fluid Dynamics [PDF]

arXiv, 2021
Clinically significant portal hypertension (CSPH) is a severe complication of chronic liver disease associated with cirrhosis, which is diagnosed by the measurement of hepatic venous pressure gradient (HVPG). However, HVPG measurement is invasive and therefore difficult to be widely applied in clinical routines.
arxiv  

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment [PDF]

, 2010
Background Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a ...
de Knegt, Robert J, Desombere, Isabelle, Haagmans, Bart, Hansen, Bettina, Janssen, Harry LA, Leroux-Roels, Geert, Orlent, Hans, Schalm, Solko W, Van Vlierberghe, Hans   +8 more
core   +1 more source